Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVHIPEC-2
2023-509049-11-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Planned start Apr 2024; status: authorised.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-509049-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509049-11-00.